BrightPath Biotherapeutics Co.,Ltd. [4594.T]
TOKYO, May 14 (Pulse News Wire) – Brightpath Biotherapeutics CO.,LTD. (4594.T) announced adjustments to its drug development pipeline strategy due to changes in the pharmaceutical industry environment.
The company will continue to focus on its core program, BP2,202, an iPSC-derived CAR-T cell therapy for cancer treatment. However, several antibody drugs targeting CD73, CD39, and TIM-3 have been excluded from the pipeline due to limited competitive advantages and reduced chances of regulatory approval based on recent clinical trial outcomes of similar products. Specifically, BP1,200 and BP1,202 (anti-CD73 and anti-CD39 antibodies) were removed because their potential to outperform existing treatments was deemed low. Similarly, BP1,210 (an anti-TIM-3 antibody) was also excluded despite efforts to enhance its design.
Despite these exclusions, the company remains committed to research involving CD39 and TIM-3 targets through ongoing programs such as BP1,212 and BP1,212. Additionally, the neoantigen vaccine BP1,209 was also excluded from further development due to high manufacturing costs and poor clinical performance compared to mRNA vaccines. The revised pipeline now focuses on key projects including iPSC-derived NKT cells (BP2,201), BCMA CAR-NKT cells (BP2,202), and HER2 CAR-T cells (BP2,301). Antibody combinations targeting solid tumors (BP1,212) and acute myeloid leukemia (BP2,202) are also part of the updated plan.
🟢 Confidence: High AI-translated content.